Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed
Drug: Bevacizumab
Drug: Cixutumumab

First Posted Date: 2010-12-21

Last Posted Date: 2019-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT01263782

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Prohibitin-TP01

First Posted Date: 2010-12-17

Last Posted Date: 2019-01-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01262664

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

TKI258 for Metastatic Inflammatory Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Dovitinib

First Posted Date: 2010-12-17

Last Posted Date: 2019-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT01262027

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

Phase 2

Terminated

Conditions: Advanced Cancers

Interventions: Dietary Supplement: Fish Oil Supplement
Drug: Atorvastatin
Other: Placebo

First Posted Date: 2010-12-14

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01259284

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Phase 2

Terminated

Conditions: Leukemia
Lymphoma

Interventions: Drug: Ofatumumab

First Posted Date: 2010-12-13

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01258933

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Delayed-Delayed Breast Reconstruction

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: Delayed Breast Reconstruction

First Posted Date: 2010-12-08

Last Posted Date: 2016-07-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT01256528

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Single Session Spine Stereotactic Radiosurgery in Metastatic Epidural Spinal Cord Compression

Phase 1

Completed

Conditions: Metastatic Epidural Spinal Cord Compression

Interventions: Procedure: Stereotactic Radiosurgery (SSRS)
Behavioral: Questionnaires

First Posted Date: 2010-12-08

Last Posted Date: 2021-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT01256554

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone Acetate
Drug: Prednisone
Drug: Dasatinib
Drug: Sunitinib

First Posted Date: 2010-12-07

Last Posted Date: 2025-01-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 190

Registration Number: NCT01254864

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Azacitidine
Drug: Sorafenib

First Posted Date: 2010-12-07

Last Posted Date: 2016-05-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT01254890

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I Study of Feasibility of Single Session Spine Stereotactic Radiosurgery (SSRS) in the Primary Management in Patients With Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression (MESCC)

Phase 1

Active, not recruiting

Conditions: Metastatic Epidural Spinal Cord Compression

Interventions: Procedure: Stereotactic Radiosurgery (SSRS)

First Posted Date: 2010-12-07

Last Posted Date: 2025-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT01254903

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy